^
2ms
PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
4ms
mTOR (Mechanistic target of rapamycin kinase) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
|
TSC1 mutation • MTOR mutation • TSC2 mutation
4ms
NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8)
4ms
PAX8 (Paired box 8)
7ms
Clinical • European regulatory
|
PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
7ms
Preclinical
|
FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)
7ms
PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1)
8ms
TP53 (Tumor protein P53) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • PBRM1 (Polybromo 1) • MDM2 (E3 ubiquitin protein ligase) • TERT (Telomerase Reverse Transcriptase) • TSC2 (TSC complex subunit 2) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)
9ms
TFE3 • MITF (Melanocyte Inducing Transcription Factor)
11ms
Clinical • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
PD-L1 expression
|
Opdivo (nivolumab)
12ms
BAP1 (BRCA1 Associated Protein 1)
|
BAP1 mutation
12ms
PD-1 (Programmed cell death 1)
1year
MITF (Melanocyte Inducing Transcription Factor)
1year
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
1year
VHL (von Hippel-Lindau tumor suppressor) • EPAS1 (Endothelial PAS domain protein 1)
|
VHL mutation
over1year
HIF1A (Hypoxia inducible factor 1, alpha subunit)
over1year
EPAS1 (Endothelial PAS domain protein 1)
|
Welireg (belzutifan)
over1year
Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)